We next examined the in vitro effects of siRNA targeting of human GDPD3 mRNA in the K562 human CML cell line as well as in primary human CD34+ CML cells isolated from BM of a chronic phase CML patient. The gene discussed is GDPD3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.